Heart Failure and MRAs: Diving Deep Into the Pivotal FINEARTS-HF Trial
Update: 2025-06-18
Description
In this podcast, Ty J. Gluckman, MD, MHA, discusses the pivotal phase III FINEARTS-HF trial and how the treatment landscape is evolving for patients with heart failure (HF) with mildly reduced or preserved ejection fraction, including:
- The emerging role of mineralocorticoid receptor antagonists in HF care
- Finerenone’s efficacy in reducing composite cardiovascular death and worsening HF events
- Why safety must be monitored, especially considering hyperkalemia risk
- Where HF guideline recommendations lack compared with the current evidence
Presenter
Ty J. Gluckman, MD, MHA
Medical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS)
Providence Heart Institute
Providence Health System
Portland, Oregon
Program page:
https://bit.ly/448XcH0
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
